Jason B. Daly Esq. Net Worth

The estimated Net Worth of Jason B. Daly is at least $570 Tysiąc dollars as of 3 March 2024. Mr Daly owns over 60,871 units of Amneal Pharmaceuticals Inc stock worth over $570,035 and over the last 3 years he sold AMRX stock worth over $0.

Wallmine is a radically better financial terminal.
Sign up in seconds, it's free!

Sign up

Already have an account? Sign in

Mr Esq AMRX stock SEC Form 4 insiders trading

Mr has made over 2 trades of the Amneal Pharmaceuticals Inc stock since 2023, according to the Form 4 filled with the SEC. Most recently he exercised 60,871 units of AMRX stock worth $508,882 on 3 March 2024.

The largest trade he's ever made was exercising 60,871 units of Amneal Pharmaceuticals Inc stock on 3 March 2024 worth over $508,882. On average, Mr trades about 27,839 units every 122 days since 2022. As of 3 March 2024 he still owns at least 68,186 units of Amneal Pharmaceuticals Inc stock.

You can see the complete history of Mr Daly stock trades at the bottom of the page.

Mr. Jason B. Daly Esq. biography

Jason B. Daly Esq. is the Sr. VP, Chief Legal Officer & Corp. Sec. at Amneal Pharmaceuticals Inc.

How old is Mr Esq?

Mr Esq is 47, he's been the Sr. VP i Chief Legal Officer & Corp. Sec. of Amneal Pharmaceuticals Inc since . There are 17 older and 5 younger executives at Amneal Pharmaceuticals Inc. The oldest executive at Amneal Pharmaceuticals Inc is Shlomo Yanai, 67, who is the Independent Director.

What's Mr Esq's mailing address?

Jason's mailing address filed with the SEC is C/O AMNEAL PHARMACEUTICALS, INC., 400 CROSSING BOULEVARD, BRIDGEWATER, NJ, 08807.

Insiders trading at Amneal Pharmaceuticals Inc

Over the last 7 years, insiders at Amneal Pharmaceuticals Inc have traded over $867,197,480 worth of Amneal Pharmaceuticals Inc stock and bought 3,818,425 units worth $12,997,905 . The most active insiders traders include Gp A, Llcbonderman Davidcou..., Holdings, Llc Aphc oraz International Ltd Fosun. On average, Amneal Pharmaceuticals Inc executives and independent directors trade stock every 18 days with the average trade being worth of $3,857,739. The most recent stock trade was executed by Andrew S Boyer on 14 August 2024, trading 62,711 units of AMRX stock currently worth $491,654.

What does Amneal Pharmaceuticals Inc do?

an american pharmaceutical company, amneal develops and produces affordable medicines. the company was built upon a family tradition of quality and integrity. everything amneal does, across the full spectrum of its business, is in service to these guiding principles. amneal is committed to constantly elevating and refining the value it delivers to its customers and patients around the globe.

Complete history of Mr Daly stock trades at Amneal Pharmaceuticals Inc

Amneal Pharmaceuticals Inc executives and stock owners

Amneal Pharmaceuticals Inc executives and other stock owners filed with the SEC include:

• Andrew Boyer,
  Executive Vice President - Commercial Operations
• Chintu Patel R.Ph, R.Ph.,
  Co-Founder, Co-CEO & Director
• Nikita Shah,
  Chief Human Resource Officer, Senior Vice President
• Andrew S. Boyer,
  Exec. VP & Chief Commercial Officer of Generics
• Anastasios G. Konidaris,
  Exec. VP & CFO
• Joseph Todisco MBA,
  Exec. VP & Chief Commercial Officer of Specialty
• Nikita Shah,
  Exec. VP and Chief HR Officer & Strategic Planning Officer
• J. Kevin Buchi,
  Independent Director
• Ted Nark,
  Independent Director
• Emily Alva,
  Independent Director
• Gautam Patel,
  Director
• Chintu Patel,
  Co-Chief Executive Officer, Co-Founder, Director
• Chirag Patel,
  President, Co-Chief Executive Officer, Director
• Paul Meister,
  Independent Chairman of the Board
• Shlomo Yanai,
  Independent Director
• John Kiely,
  Independent Director
• Jeffrey George,
  Independent Director
• Chintu Patel R.Ph., R.Ph,
  Co-Founder, Co-CEO & Director
• Chirag K. Patel,
  Co-Founder, Co-CEO, Pres & Director
• Joseph Todisco,
  Senior Vice President - Specialty Commercial
• Apurva Saraf,
  Senior Vice President - Corporate Development
• Joseph Greer,
  Senior Vice President - Global Quality Management
• Stephen Manzano,
  Senior Vice President, General Counsel & Corporate Secretary
• Sanjay Jain,
  President - India
• Anastasios Konidaris,
  Chief Financial Officer, Senior Vice President
• Jason B. Daly Esq.,
  Sr. VP, Chief Legal Officer & Corp. Sec.
• Dr. Nikunj Patel,
  Head of Ops & Exec. VP of Amneal Pharmaceuticals (India) Pvt Ltd
• Sanjiv Patel,
  Sr. VP of Operations
• Stephen J. Manzano,
  Sr. VP, Gen. Counsel & Corp. Sec.
• Anthony DiMeo,
  Sr. Director of Investor Relations
• Sheldon Hirt,
  SVP, GC & Corp. Sec.
• Jean Selden Greene,
  Director
• Holdings, Llc Aphc,
  10% owner
• Robert L Burr,
  Director
• Bryan M. Reasons,
  CFO
• Robert A Stewart,
  President and CEO
• Dharmendra Rama,
  Director
• Janet S. Vergis,
  Director
• Peter R Terreri,
  Director
• Paul Bisaro,
  Executive Chairman
• David A Buchen,
  SVP, Chief Legal Officer
• Todd P. Branning,
  SVP and CFO
• Pradeep Bhadauria,
  SVP, Chief Scientific Officer
• International Ltd Fosun,
  10% owner
• Gustavo Pesquin,
  See Remarks
• Gp A, Llcbonderman Davidcou...,
  
• Tasos Konidaris,
  Executive Vice President & CFO
• Jason B. Daly,
  SVP, Chief Legal Officer
• Deborah M. Autor,
  Director
• Dipan Patel,
  
• Tushar Bhikhubhai Patel,
  10% owner